Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Lamotrigine (BW430C) is an Anti-epileptic Agent and Mood Stabilizer. The physiologic effect of lamotrigine is by means of Decreased Central Nervous System Disorganized Electrical Activity.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
200 mg | In stock | $ 31.00 | |
500 mg | In stock | $ 46.00 | |
1 g | In stock | $ 72.00 | |
5 g | In stock | $ 271.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 48.00 |
Description | Lamotrigine (BW430C) is an Anti-epileptic Agent and Mood Stabilizer. The physiologic effect of lamotrigine is by means of Decreased Central Nervous System Disorganized Electrical Activity. |
Targets&IC50 | 5-HT (human platelets):240 μM, 5-HT (rat brain synaptosomes):474 μM |
In vitro | Lamotrigine is active in electrically induced EEG after-discharge tests, indicating its ability to counteract simple and complex partial seizures. It demonstrates antiepileptic effects in mice and rats, preventing hind-limb extension induced by both MES (maximal electroshock) and pentylenetetrazole. The peak effects of Lamotrigine occur 1 hour post-administration, with a duration exceeding 24 hours. Intravenous administration of Lamotrigine at doses greater than 5 mg/kg in rats results in a dose-dependent reduction in after-discharge duration. |
In vivo | In rat cortical brain tissues cultured with 10 mg/L veratridine, Lamotrigine inhibited the release of glutamate and aspartate (both with an ED50 of 5.38 mg/L) twice as effectively as it inhibited the release of GABA (ED50 of 11.2 mg/L), without affecting the basal release of glutamate. Lamotrigine stabilizes presynaptic neuronal membranes by blocking voltage-dependent sodium channels, thereby preventing the release of excitatory neurotransmitters, especially glutamate and aspartate. It does not induce phencyclidine (PCP)-like central nervous system effects, does not act through direct inhibition of NMDA receptors, and may avoid the adverse effects associated with NMDA blockade. |
Kinase Assay | Whole Cell [3H]R1881 Binding Assay: Fibroblasts are grown to confluence in five or six 150 cm2 tissue culture flasks for routine assay. This usually requires 4-6 weeks from the time of the initial seeding of the cell line. All studies are performed between passages 3-20. Two days before assay, the medium is changed to one lacking fetal calf serum. This is repeated again 24 hours before assay. Competition assays are performed with 0.5-1.0 nM [3H]R1881 and increasing amounts of the nonradioactive compounds. Binding to low affinity sites is determined in the presence of 5 × 10-7 M R1881 and is subtracted from whole cell binding of [3H]R 1881 obtained in the absence of any inhibitor to assess binding to 5 high affinity site |
Synonyms | LTG, BW430C |
Molecular Weight | 256.09 |
Formula | C9H7Cl2N5 |
CAS No. | 84057-84-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 25.6 mg/mL (100 mM)
Ethanol: 2.6 mg/mL (10 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Lamotrigine 84057-84-1 Autophagy GPCR/G Protein Membrane transporter/Ion channel Neuroscience Sodium Channel 5-HT Receptor Lennox-Gastaut syndrome tonic-clonic seizure Na+ channels epilepsy inhibit seizure Na channels LTG BW430C focal seizure Inhibitor inhibitor